New Group Will Promote Decentralized Clinical Trials

Several of the world’s healthcare, bioscience and pharmaceutical firms, including such global leaders as AstraZeneca, Pfizer and Biogen have joined together to accelerate the adoption of decentralized clinical trials and research.

In the planning stage before the coronavirus pandemic, the Decentralized Trials & Research Alliance (DTRA) formally announced its founding this month. With an initial membership of some 50 organizations, the alliance declared its mission to “make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.”

Explained Amir Kalali, MD, co-convenor of DTRA, “The benefits of decentralized research methodologies have been apparent for some time, but adoption has been slow due to many factors including culture and the lack of a forum for stakeholders to collaborate.

“The COVID-19 pandemic has forced organizations to adopt decentralized methodologies which have the potential to broadly accelerate drug development.”

Decentralized trials, also (imprecisely) referred to as virtual trials, allow patients to participate without the need to regularly or ever visit a research site. Through telemedicine visits, remote monitoring, wearables and smartphones, researchers can often collect as much or more data in many cases, and often more reliable data, than by requiring in-person visits.

Several months ago we blogged about the increasing use of decentralized trials – those that are entirely remote and those that include occasional face-to-face visits. In that June post we noted that “prompted by the COVID-19 pandemic, and given the blessing of the FDA, broad acceptance of decentralized trials is becoming a reality.”

Speaking at the virtual BIO 2020 conference, panelists agreed that the foothold COVID gave to decentralized trials will continue to grow, in large part because of its patient benefits. With participants freed from having to travel to research sites, it opens opportunities to recruit underrepresented populations. One example, cited by a panelist, was the potential now to include autistic patients.

DTRA, in its founding announcement, said, “Inclusion of representative patient populations in clinical trials by race, age, and geographic location has long been an operational challenge. Decentralized approaches to conducting research facilitate participation by a more diverse patient population and could ease COVID-19-imposed difficulties for both patients and clinical investigators.”

Added Craig Lipset, DTRA co-convener, “Now is the time to share ideas and insights that will chart the future course of clinical trials, accelerating drug development and saving lives.”

Image by PublicDomainPictures

#WeAreGreenKey: Spotlight on Lucas Leitenberger
Architecture + Engineering

#WeAreGreenKey: Spotlight on Lucas Leitenberger

Biotech vs. Techbio: A Nexus of Biology and Tech
General Interest

Biotech vs. Techbio: A Nexus of Biology and Tech

Cancer Vaccines: A New Hope
General Interest

Cancer Vaccines: A New Hope

Navigating Quarterly Reviews with Confidence
General Interest

Navigating Quarterly Reviews with Confidence

#WeAreGreenKey: Spotlight on Meryl Schoen
General Interest Professional Support

#WeAreGreenKey: Spotlight on Meryl Schoen

Mastering Hiring Algorithms as a Candidate
General Interest

Mastering Hiring Algorithms as a Candidate

Tips for Creating Effective Corporate Videos for Social Media
General Interest

Tips for Creating Effective Corporate Videos for Social Media

The Power of Video on Corporate Social Media
General Interest

The Power of Video on Corporate Social Media

#WeAreGreenKey: Spotlight on Antonia Piazza
General Interest

#WeAreGreenKey: Spotlight on Antonia Piazza

Strategies for Equitable Employee Development
General Interest

Strategies for Equitable Employee Development

Anthropic Unveils Claude 3: Redefining AI Chatbots with Enhanced Capabilities
Information Technology

Anthropic Unveils Claude 3: Redefining AI Chatbots with Enhanced Capabilities

#WeAreGreenKey: Spotlight on Mike Bosco
Accounting + Finance General Interest

#WeAreGreenKey: Spotlight on Mike Bosco

Marketing Strategies: 2024 Trends and Strategies for Success
General Interest

Marketing Strategies: 2024 Trends and Strategies for Success

The Essence of Marketing Strategy: Driving Business Success (Part II)
General Interest

The Essence of Marketing Strategy: Driving Business Success (Part II)

The Essence of Marketing Strategy: Driving Business Success
General Interest

The Essence of Marketing Strategy: Driving Business Success

Mastering Task Prioritization for Stress Reduction
General Interest

Mastering Task Prioritization for Stress Reduction

Crafting the Future: Delving into AI as a College Major
General Interest Information Technology

Crafting the Future: Delving into AI as a College Major

Mary-Kate Bula Selected as Assistant Coach of the USA Women’s Flag Football National Team
General Interest Pharma

Mary-Kate Bula Selected as Assistant Coach of the USA Women’s Flag Football National Team

Leveraging LinkedIn Polls: A Strategic Tool for Business Insights
General Interest

Leveraging LinkedIn Polls: A Strategic Tool for Business Insights

#WeAreGreenKey: Spotlight on Kyle Gierke
General Interest Healthcare

#WeAreGreenKey: Spotlight on Kyle Gierke

Latest Blog Posts
View All Posts
#WeAreGreenKey: Spotlight on Lucas Leitenberger

#WeAreGreenKey: Spotlight on Lucas Leitenberger

Welcome back to #WeAreGreenKey, where we shine a spotlight on our powerhouse recruiting team.  We recently met up with Lucas...
Read More
Biotech vs. Techbio: A Nexus of Biology and Tech

Biotech vs. Techbio: A Nexus of Biology and Tech

In the dynamic world of scientific innovation, two terms have emerged as guiding lights: Biotech and Techbio. These terms encapsulate...
Read More
Cancer Vaccines: A New Hope

Cancer Vaccines: A New Hope

Cancer vaccines stand as a beacon of hope in the realm of cancer treatment, diverging from traditional vaccines designed to...
Read More